cis-Resveratrol
Based on 1 publication(s) in Google Scholar
cis-Resveratrol exhibits signifcant antiviral activity. cis-Resveratrol inhibits enteroviruses with IC50s of 12.2 µM and 37.6 µM for coxsackievirus B3 (CVB3) and enterovirus 71 (EV71), respectively. cis-Resveratrol is the inhibitor for NF-κB signaling pathway.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.84%
- CAS No.: 61434-67-1
- 화학식: C14H12O3
- 분자량:228.25
-
보관:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) cis-Resveratrol
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | GI50 |
15.5 μg/mL
Compound: 1c
|
Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human BxPC3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| BXPC-3 | GI50 |
15.5 μg/mL
Compound: Z-3
|
Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| BXPC-3 | GI50 |
15.5 μg/mL
Compound: 10
|
In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line.
In vitro growth inhibition of BXPC-3 (human pancreatic adenocarcinoma) cell line.
|
[PMID: 12036362] |
| DU-145 | GI50 |
10.2 μg/mL
Compound: 1c
|
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human DU145 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| DU-145 | GI50 |
10.2 μg/mL
Compound: Z-3
|
Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| DU-145 | GI50 |
10.2 μg/mL
Compound: 10
|
In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line.
In vitro growth inhibition of DU-145 (human prostate carcinoma) cell line.
|
[PMID: 12036362] |
| HCT-116 | IC50 |
25.1 μM
Compound: Cis-RSV
|
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition
Anticancer activity against human HCT-116 cells assessed as cell growth inhibition
|
[PMID: 32485531] |
| HL-60 | IC50 |
42 μM
Compound: 9c
|
In vitro inhibitory concentration against proliferation of HL60 cells
In vitro inhibitory concentration against proliferation of HL60 cells
|
[PMID: 12877593] |
| KM-20L2 | GI50 |
22 μg/mL
Compound: 1c
|
Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human KM20L2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| KM-20L2 | GI50 |
22 μg/mL
Compound: Z-3
|
Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| KM-20L2 | GI50 |
22 μg/mL
Compound: 10
|
In vitro growth inhibition of KM20L2 cell line.
In vitro growth inhibition of KM20L2 cell line.
|
[PMID: 12036362] |
| MCF7 | GI50 |
14.8 μg/mL
Compound: 1c
|
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| MCF7 | GI50 |
14.8 μg/mL
Compound: Z-3
|
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| MCF7 | GI50 |
14.8 μg/mL
Compound: 10
|
Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase
Cell growth inhibition of breast MCF-7 cells, expressed as 50% reduction in the net protein increase
|
[PMID: 12036362] |
| MCF7 | IC50 |
28.38 μM
Compound: RSV
|
Cytotoxicity against ER-positive human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against ER-positive human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24119558] |
| NCI-H460 | GI50 |
13.2 μg/mL
Compound: 1c
|
Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human NCI-H460 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| NCI-H460 | GI50 |
13.2 μg/mL
Compound: Z-3
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| NCI-H460 | GI50 |
13.2 μg/mL
Compound: 10
|
In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line.
In vitro growth inhibition of NCI-H460 (human non-small cell lung carcinoma) cell line.
|
[PMID: 12036362] |
| P388 | ED50 |
24.4 μg/mL
Compound: Z-3
|
Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against mouse P388 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| P388 | ED50 |
24.4 μg/mL
Compound: 10
|
In vitro inhibition of P388 (murine leukemia) cell proliferation.
In vitro inhibition of P388 (murine leukemia) cell proliferation.
|
[PMID: 12036362] |
| SF-268 | GI50 |
5 μg/mL
Compound: 1c
|
Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
Growth inhibition of human SF268 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19719153] |
| SF-268 | GI50 |
5 μg/mL
Compound: Z-3
|
Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay
Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 19709889] |
| SF-268 | GI50 |
5 μg/mL
Compound: 10
|
In vitro growth inhibition of central nervous system SF-268 cell line.
In vitro growth inhibition of central nervous system SF-268 cell line.
|
[PMID: 12036362] |
| SK-BR-3 | IC50 |
41.22 μM
Compound: RSV
|
Cytotoxicity against ER-negative human SKBR3 cells assessed as growth inhibition after 72 hrs by MTT assay
Cytotoxicity against ER-negative human SKBR3 cells assessed as growth inhibition after 72 hrs by MTT assay
|
[PMID: 24119558] |
| SW480 | IC50 |
90 μM
Compound: 2
|
Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs
Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs
|
[PMID: 20395019] |
cis-Resveratrol (0-100 μM, 3-6 h) inhibits the expression of genes associated with the NF-κB signaling pathway, including NFnBL1, ICAM-1, Scya2 (MCP-1), RIP, and TLR7, inhibits the expression of pro-inflammatory cytokines (M-CSF, GM-CSF, G-CSF) and chemokines (RANTES), upregulates the expression of IL-6 and TNF-α in mouse peritoneal macrophages[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:mouse peritoneal macrophages
-
Concentration:100 μM
-
Incubation Time:3-6 h
-
Result:Upregulated the expression of IL-6 and TNF-α.
Chemical Information
-
CAS No. 61434-67-1
-
Appearance Solid
-
분자량 228.25
-
화학식 C14H12O3
-
Color White to off-white
-
SMILES
OC1=CC(/C=C\C2=CC=C(O)C=C2)=CC(O)=C1
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Liver Int
miR-18a-5p/PXR/SREBP2 Was Involved in MAFLD Associated With Methyl Tert-Butyl Ether Among Petrol Station Workers. [Abstract]2025 Feb;45(2):e16246. PMID: 39821525
용액&용해도
DMSO : 125 mg/mL (547.65 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (9.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (9.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Mira Oh, et al. Chemical components from the twigs of Caesalpinia latisiliqua and their antiviral activity. J Nat Med. 2020 Jan;74(1):26-33. [Content Brief]
[2]. Leiro J, et al., Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling. Int Immunopharmacol. 2005 Feb;5(2):393-406. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3812 mL | 21.9058 mL | 43.8116 mL | 109.5290 mL |
| 5 mM | 0.8762 mL | 4.3812 mL | 8.7623 mL | 21.9058 mL | |
| 10 mM | 0.4381 mL | 2.1906 mL | 4.3812 mL | 10.9529 mL | |
| 15 mM | 0.2921 mL | 1.4604 mL | 2.9208 mL | 7.3019 mL | |
| 20 mM | 0.2191 mL | 1.0953 mL | 2.1906 mL | 5.4765 mL | |
| 25 mM | 0.1752 mL | 0.8762 mL | 1.7525 mL | 4.3812 mL | |
| 30 mM | 0.1460 mL | 0.7302 mL | 1.4604 mL | 3.6510 mL | |
| 40 mM | 0.1095 mL | 0.5476 mL | 1.0953 mL | 2.7382 mL | |
| 50 mM | 0.0876 mL | 0.4381 mL | 0.8762 mL | 2.1906 mL | |
| 60 mM | 0.0730 mL | 0.3651 mL | 0.7302 mL | 1.8255 mL | |
| 80 mM | 0.0548 mL | 0.2738 mL | 0.5476 mL | 1.3691 mL | |
| 100 mM | 0.0438 mL | 0.2191 mL | 0.4381 mL | 1.0953 mL |
cis-Resveratrol Related Classifications
HY-16561A Related Classifications
Powered by Bioz